Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2005-07-19
2005-07-19
Wortman, Donna C. (Department: 1648)
Chemistry: molecular biology and microbiology
Vector, per se
C514S04400A, C424S189100, C424S227100, C530S327000, C530S328000
Reexamination Certificate
active
06919203
ABSTRACT:
Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.
REFERENCES:
patent: 3645852 (1972-02-01), Axen et al.
patent: 4235877 (1980-11-01), Fullerton
patent: 4428941 (1984-01-01), Galibert et al.
patent: 4487715 (1984-12-01), Nitecki et al.
patent: 4599230 (1986-07-01), Milich et al.
patent: 4599231 (1986-07-01), Milich et al.
patent: 4659569 (1987-04-01), Mitsuhashi et al.
patent: 4818527 (1989-04-01), Thornton et al.
patent: 4882145 (1989-11-01), Thornton et al.
patent: 4935235 (1990-06-01), Rutter et al.
patent: 5017558 (1991-05-01), Vyas
patent: 5019386 (1991-05-01), Machida et al.
patent: 5039522 (1991-08-01), Neurath
patent: 5100662 (1992-03-01), Bolcsak et al.
patent: 5133961 (1992-07-01), Ellis et al.
patent: 5143726 (1992-09-01), Thornton et al.
patent: 5158769 (1992-10-01), Neurath et al.
patent: 5780036 (1998-07-01), Chisari
patent: 5788969 (1998-08-01), Chisari
patent: 5840303 (1998-11-01), Chisari et al.
patent: 5932224 (1999-08-01), Chisari
patent: 6322789 (2001-11-01), Vitiello et al.
patent: 6607727 (2003-08-01), Chisari et al.
patent: 2003/0171538 (2003-09-01), Chisari
patent: 013 828 (1980-08-01), None
patent: 105 481 (1984-04-01), None
patent: 271 302 (1987-12-01), None
patent: 293 201 (1988-11-01), None
patent: 326 111 (1989-01-01), None
patent: 327369 (1989-08-01), None
patent: 431 327 (1991-06-01), None
patent: 469 281 (1992-02-01), None
patent: 534 615 (1993-03-01), None
patent: 2034323 (1980-06-01), None
patent: 161999 (1985-08-01), None
patent: 64-025800 (1989-01-01), None
patent: WO 92/00753 (1992-01-01), None
patent: WO 93/03753 (1993-03-01), None
patent: WO 94/03205 (1994-02-01), None
patent: WO 94/20127 (1994-09-01), None
patent: WO 94/25060 (1994-11-01), None
patent: WO 95/03777 (1995-02-01), None
patent: WO 95/04817 (1995-02-01), None
Deres et al., In vivo priming of virus specific cytotoxic T lymphocytes with synthetic lipopeptide vaccine. Nature, Nov. 30, 1989, 342:561-564.
Rotzschke et al., Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells. Nature, Nov. 15, 1990, 348:252-254.
Bertoletti et al., HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B nucleocapsid antigen PNAS USA, Dec. 1991, 88:10445-10449.
Penna et al., Hepatitis B virus (HBV) specific cytotoxic T cell (CTL) response in humans: Characterization of HLA calss II-restricted CTLs that recognize endogenously synthesized HBV envelope antigens. J. Virol., Feb. 1992, 66:1193-1198.
Bertoletti, A. et al. “Definition of a minimal optimal cytotoxic T-cell epitope within the hepatitis B virus nucleocapsid protein,”Virology, 1993, 67(4):2376-2380.
Carbone, F.R. and M.J. Bevan “Induction of Ovalbumin-Specific Cytotoxic T Cells by In Vivo Peptide Immunization”J. Exp. Med., Mar. 1989, 169:603-612.
Collins, D.S. et al. “Processing of Exogenous Liposome-Encapsulated Antigens In Vivo Generates Class I MHC-Restricted T Cell Response”J. Immunology, 1992, 148:3336-3341.
Lee, K.K. et al. “Cross-Reactive and Strain-Specific Antipeptide Antibodies toPseudomonas aeruginosaPAK and PAO Pili”Infection and Immunity, Sep. 1990, 58(9):2727-2732.
Mack, D.H. et al. “Hepatitis B Virus Particles Contain a Polypeptide Encoded by the Largest Open Reading Frame: A Putative Reverse Transcriptase”J. Virology, Dec. 1988, 62(12):4786-4790.
Pasek, M. et al. “Hepatitis B virus genes and their expression inE. coli” Nature, Dec. 6, 1979, 282:575-579.
Reddy, R. et al. “In Vivo Cytotoxic T Lymphocyte Induction with Soluble Proteins Administered in Liposomes”J. Immunology, Mar. 1, 1992, 148(5):1585-1589.
Yssel, H. et al. “T Cell Activation-Inducing Epitopes of the House Dust Mite AllergenDer pI”J. Immunology, Feb. 1, 1992, 148(3):738-745.
Bertoletti, A. et al. “Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells”Nature, Jun. 2, 1994, 369:407-410.
Bichko et al. “Subtype ayw variant of hepatitis B virus”FEBS Lett., 1985, 185:208-212.
Bowie et al. “Deciphering the Message In Protein Sequences: Tolerance to Amino Acid Substitutions”Science, 1990, 247:1306-1310.
Carbone et al. “Induction of Cytotoxic T Cells by Primary in vitro Stimulation with Peptides”J. Exp. Med., 1988, 167:1767-1779.
De Magistris, M.T. et al. “Antigen Analog-major histocompatibility complexes act as antagonists of the T cell receptor”Cell, Feb. 21, 1992, 68(4):625-634.
Falk et al. “Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules”Nature, May 1991, 351:290-296.
Galibert et al. “Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned inE. coli” Nature, 1979, 281:646-650.
Hilleman “Comparative Biology and Pathogenesis of AIDS and Hepatitis B Viruses: Related but Different”AIDS Res. Hum. Retrovir., 10:1409-1419.
Jameson, S.C. et al. “Clone-specific T cell receptor antagonists of major histocompatibility complex class I-restricted cytotoxic T cells”J. Exp. Med., Jun. 1, 1993, 177(6):1541-1550.
Kumar et al. “Amino acid variations at a single residue in an autoimmune peptide profoundly affect its properties”PNAS USA, 1990, 87:1337-1341.
Lewin “When Does Homology Mean Something Else?”Science, 1987, 237:1570.
Milich et al. “Immune Response to Hepatitis B Virus Core Antigen (HBcAg): Localization of T Cell Recognition Sites Within HBcAg/HBeAg”J. Immunol., 1987, 139:1223-1231.
Nayersina et al. “HLA A2 Restricted Cytotoxic T Lymphocyte Responses to Multiple Hepatitis B Surface Antigen Epitopes during Hepatitis B Virus Infection”J. Immunol., 1991, 150:4659-4671.
Reeck et al. “Homology in Proteins and Nucleic Acids: A Terminology Muddle and a Way out It”Cell, 1987, 50:667.
Ruppert, J. et al. “Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules”Cell, 1993, 74(5):929-937.
Tong et al. “Active Hepatitis B Virus Replication in the Presence of Anti-HBe is Associated with Viral Variants Containing on Inactive Pre-C Region”Virology, 1990, 176:596-603.
Vitiello, A et al. “Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV Infection. I. Induction of a primary cytotoxic T lymphocyte response in humans”J. of Clin. Invest., Jan. 1995, 95(1):341-349.
Greenstein, J.L. et al. “A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120”J. Immunology, 1992, 148:3970-3977.
Watari, E. et al. “A synthetic peptide induces long-term protection from lethal infection with herpes simplex virus 2”J. Exp. Med., 1987, 165(2):459-470.
Hopp, T.P. “Immunogenicity of a synthetic HBsAg peptide: enhancement by conjugation to a fatty acid carrier”Mol. Immunol., 1984, 21(1):13-16.
Bessler, W.G. et al. “The synthetic analog of bacterial lipoprotein are potent immunoadjuvants in combination with or covalently linked to antigen”Prog. Leukocyte Biol., 1986, 5:337-344.
Parker et al. “Peptide Binding to HLA-A2 and HLA-B27 Isolated fromE. coli” J. Biol. Chem., 1992, 267:5451-5459.
Penna et al. “Cytotoxic T Lymphocytes Recognize an HLA-A2-restricted Epitope within the Hepatitis B Virus Nucleocapsid Antigen”Exp. Med., 1991, 174:1565-1570.
Ferrari et al. “Identification of Immunodominant T Cell Epitopes of the Hepatitis B Virus Nucleocapsid Antigen”J. Clin. Invest., 1991, 88:214-222.
Roitt et al. “Immunology”, 3rdEd., Mosby, St. Louis, p. 4.14,
Saliwanchik Lloyd & Saliwanchik
The Scripps Research Institute
Wortman Donna C.
LandOfFree
Peptides for inducing cytotoxic T lymphocyte responses to... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptides for inducing cytotoxic T lymphocyte responses to..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptides for inducing cytotoxic T lymphocyte responses to... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3422583